Navigation Links
BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
Date:3/24/2008

ion. This can decrease the efficacy of the current medication and may compromise future treatment options. To date, studies have shown that multiple mutations are required to develop BARACLUDE(R) (entecavir) resistance.

"These long-term BARACLUDE data continue to support the observations seen in the first years of treatment and are reflective of BARACLUDE's high genetic barrier to resistance," said Helena Brett-Smith, M.D., Group Director of Clinical Research at Bristol-Myers Squibb. "More importantly, we believe the data support BARACLUDE as an important initial treatment choice for chronic hepatitis B, which is a disease that results in a large global health burden."

About the Analysis

More than 700 patients across six studies initiated therapy on BARACLUDE and were monitored for treatment response and resistance.

The year five analysis expands upon previous analyses, adding in information on patients who received treatment with BARACLUDE during the fifth year of follow-up (n=108 for patients in nucleoside-naive studies and n=33 for patients in lamivudine-refractory studies).

In this comprehensive analysis, all patients enrolled in Bristol-Myers Squibb clinical trials ETV-014, -015, -022, -027, -026 and -901 who experienced a virologic breakthrough(1) or whose virus had not yet reached undetectable levels(2) at weeks 48, 96, 144, 192, 240 or end of dosing, were sequenced to determine if any changes occurred in the genetic code of the virus that would result in resistance or loss of effectiveness of BARACLUDE.

Nucleoside-naive patients in this analysis were initially treated with BARACLUDE 0.5 mg in studies ETV-022 and -027 and continued treatment with BARACLUDE 1 mg by enrolling in study ETV-901 with a treatment gap of less than or equal to 35 days. Lamivudine-refractory patients in this analysis initiated therapy on BARACLUDE 1 mg in studies ETV-014, -015, and -026 and continued treatment in study ETV-901 with a treatment
'/>"/>

SOURCE Bristol-Myers Squibb
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Carpet One Floor & Home Continues Making Dramatic Strides in Funding Breast Cancer Research and Awareness
2. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
3. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
4. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
5. Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss
6. Raven Announces Continued Enrollment of Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
7. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
10. Facet Solutions Enjoys Continued Clinical Success With the Anatomic Facet Replacement System (AFRS(TM))
11. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014 In the latest call ... sexual dysfunction, more than 60 doctors and leading medical ... letter questioning the Food and Drug Administration,s (FDA) decision ... form of male sexual dysfunction compared with ZERO for ... to act for women by approving the first-ever drug ...
(Date:8/1/2014)... , Aug. 1, 2014 RoundTable Healthcare ... exclusively on the healthcare industry, announced today the ... Lubrizol Corporation ("Lubrizol"). Lubrizol, a Berkshire Hathaway company, ... supplies technologies to customers in the global transportation, ... were not disclosed. Vesta is an ...
(Date:8/1/2014)... , Aug. 1, 2014 Aspire Technology Partners (Aspire) ... Gold Star from Cisco. This designation recognizes Aspire for delivering ... States of America . "Achieving exceptional results ... John C. Harris , President and CEO of Aspire. "We ... with their Gold Star award and are proud to be ...
Breaking Medicine Technology:60+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3RoundTable Healthcare Partners Announces Sale of Vesta Funding, Inc. to The Lubrizol Corporation 2Aspire Technology Partners Recognized By Cisco For Excellence In Customer Satisfaction 2
... Aug. 1, 2011 Reportlinker.com announces that ... in its catalogue: Insulin- ... This package contains 14 ... European countries: Austria, Belgium, Denmark, Finland, France, ...
... Aug. 1, 2011 Reportlinker.com announces that ... in its catalogue: Vaccines ... http://www.reportlinker.com/p0578257/Vaccines---Eastern-Europe.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This package contains ... Eastern European countries: Bulgaria, Czech Republic, Estonia, ...
Cached Medicine Technology:Insulin- Western Europe 2Vaccines - Eastern Europe 2
(Date:8/1/2014)... 2014 According to new market ... (Asia-Pacific, North America, Europe, & ROW), by Vehicle ... Type (Gasoline & Diesel), by After-Treatment Device (DPF, ... & Forecasts to 2019", defines and segments the ... of major countries in all the regions, and ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The North ... endpoint security solutions market in North America with analysis ... grow from around $3.53 billion in 2014 to $4.77 ... 2014 to 2019. , Browse through the TOC of ... an idea of the in-depth analysis provided. It also ...
(Date:8/1/2014)... 2014 For years, proponents have praised ... study conducted by the Ohio State University, ... behind in terms of their health and development, raising ... best for their baby. So does this new research ... Steven Shapiro , chair of Pediatrics at Abington Memorial ...
(Date:8/1/2014)... Over the past five years, ... technologies that have enabled cosmetic dentists to provide ... Moreover, the burgeoning elderly population has stimulated demand ... Due to long-term use of medications, which may ... dental fillings, veneers and implants. As more elderly ...
(Date:8/1/2014)... YORK, NY August 1, 2014 The ... trials and first report investigations that will be ... 2014 scientific symposium. TCT, the world,s premier educational ... place September 13 17, 2014 at the ... , Clinical research data presented at TCT often ...
Breaking Medicine News(10 mins):Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 2Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 4
... and WINSTON-SALEM, N.C., March 27 Prince William ... Carolina-based Novant Health, both regional not-for-profit health systems, ... intent to merge. The partnership will provide ... to western Prince William County. "We chose to ...
... covers the entire spectrum - from medical imaging, ... March 27 /PRNewswire/ -- Siemens Healthcare ( ... commitment to excellence "From Prevention to Follow-up" at ... College of Cardiology (ACC), March 29-31 in Orlando, ...
... team of scientists at Emory University School of Medicine ... inflammatory signals in the blood. The finding could lead ... antioxidants in the diet and for reducing the impact ... to intravenous or tube feeding. , The results are ...
... Analysis shows most documents require reading skills beyond those ... -- This one should come as no surprise to ... that outlines your expectations for medical care, is usually ... that you need college-level reading skills to understand ...
... Beauty Show, March 28-30 in Chicago, is dedicated ... doing so, the Show raises serious and decades ... salons. Salon products are generally dispensed from bulk ... is the cumulative contamination of air, particularly in ...
... 27 Cord Blood America, Inc. (OTC Bulletin Board: ... ( http://www.cordblood-america.com ) focused on ... families nationwide and internationally, said today it strongly supports ... U.S. House of Representatives.The legislation will provide tax incentives ...
Cached Medicine News:Health News:Prince William Health System and Novant Health Agree on Partnership to Expand Quality Healthcare in Northern Virginia 2Health News:Prince William Health System and Novant Health Agree on Partnership to Expand Quality Healthcare in Northern Virginia 3Health News:Siemens Highlights Cardiology Excellence from Prevention to Follow-up at ACC 2009 2Health News:Siemens Highlights Cardiology Excellence from Prevention to Follow-up at ACC 2009 3Health News:Siemens Highlights Cardiology Excellence from Prevention to Follow-up at ACC 2009 4Health News:Siemens Highlights Cardiology Excellence from Prevention to Follow-up at ACC 2009 5Health News:Siemens Highlights Cardiology Excellence from Prevention to Follow-up at ACC 2009 6Health News:Siemens Highlights Cardiology Excellence from Prevention to Follow-up at ACC 2009 7Health News:Targeting oxidized cysteine through diet could reduce inflammation and lower disease risk 2Health News:Patients' Bill of Rights Too Tough to Read 2Health News:Patients' Bill of Rights Too Tough to Read 3Health News:America's Beauty Show Challenges Toxic Salons 2Health News:America's Beauty Show Challenges Toxic Salons 3Health News:Cord Blood America Applauds Congressional Effort Supporting Cord Blood Storage 2
CapSureSP Novus 5594 is a J-shaped, endocardial, tined pacing lead. provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but wi...
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The Guidant Fineline II Sterox is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The electrically active helix of CapSureFix Novus lead is designed to extend easily for active fixation and retract for venous passage....
Medicine Products: